36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details
臨床試験数 : 160 / 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124
Showing 1 to 7 of 7 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-003890-91-PL (EUCTR) | 29/09/2020 | 13/11/2018 | Treatment of wound in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal injury by biological dressing made of mesynchemal stem cells seeded on acellular human skin. Treatment of wound in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal ... | The development of innovative advanced therapy medicinal product (biological dressing of the human race) in the treatment of Epidermolysis Bullosa (EB) and other chronic wounds. The development of innovative advanced therapy medicinal product (biological dressing of the human r ... | BIOOPA dressing will be used in the treatment of wounds in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal injury (second degree burn). MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] BIOOPA dressing will be used in the treatment of wounds in the course of Epidermolysis Bullosa, chro ... | Product Name: BIOOPA dressing INN or Proposed INN: Human Allogeneic WJ-MSCs Other descriptive name: WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS Product Name: BIOOPA dressing INN or Proposed INN: Human Allogeneic WJ-MSCs Other descriptive name: WH ... | Medical University of Warsaw | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 1;Phase 2 | Poland | ||
| 2 | JPRN-UMIN000028366 | 2017/06/21 | 25/07/2017 | A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis ... | A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. - A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis ... | dystrophic epidermolysis bullosa | ISN001, the sheet containing allogenic adipose derived mesenchymal stromal cells (1000000/sheet), is applied to the lesion(s) once a week up to 8 times ISN001, the sheet containing allogenic adipose derived mesenchymal stromal cells(1000000/sheet), is ... | Ishin Pharmaceutical Co. Ltd. | NULL | Complete: follow-up complete | 6years-old | 70years-old | Male and Female | 5 | Phase 1,2 | Japan |
| 3 | NCT02323789 (ClinicalTrials.gov) | June 2015 | 18/12/2014 | Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa | A Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa A Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cellsin Adults With Recessive Dystrophi ... | Recessive Dystrophic Epidermolysis Bullosa | Drug: Mesenchymal stromal cells | King's College London | NULL | Active, not recruiting | 18 Years | 65 Years | All | 10 | Phase 1/Phase 2 | United Kingdom |
| 4 | EUCTR2014-004500-30-GB (EUCTR) | 13/02/2015 | 22/12/2014 | A prospective phase I/II study to evaluate the use of mesenchymal stromal (stem) cells for the treatment of skin disease in adults with recessive dystrophic epidermolysis bullosa A prospective phase I/II study to evaluate the use of mesenchymal stromal (stem) cells for the treat ... | A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa - ADSTEM A phase I/II study evaluating allogeneic mesenchymal stromal cellsin adults with recessive dystrophi ... | Recessive dystrophic epidermolysis bullosa;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive dystrophic epidermolysis bullosa;Therapeutic area: Diseases [C] - Skin and Connective Tiss ... | Product Name: Allogeneic mesenchymal stromal cells Product Code: TC-MSC | King's College London | Guy's and St Thomas NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 10 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ... | United Kingdom | ||
| 5 | EUCTR2012-000605-72-NL (EUCTR) | 06/02/2014 | 12/08/2013 | Stem cell transplantation with cord blood and mesenchymal stem cells after reduced intensity conditioning for severe forms of the blistering disease epidermolysis bullosa Stem cell transplantation with cord blood and mesenchymal stem cells after reduced intensity conditi ... | Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa - CB+MSCforEB Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal ce ... | The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] The source population consists of patients referred to or within the UMC Groningen because they have ... | Product Name: TC-MSC INN or Proposed INN: Mesenchymal stromal cells Trade Name: Busilvex Trade Name: Fludarabine Product Name: FLudarabine Trade Name: THYMOGLOBULINE Product Name: Thymoglobuline Product Name: TC-MSC INN or Proposed INN: Mesenchymal stromal cells Trade Name: Busilvex Trade Name: Fl ... | Universitair Medisch Centrum Utrecht | NULL | Not Recruiting | Female: yes Male: yes | 11 | Phase 2 | Netherlands | ||
| 6 | EUCTR2012-001394-87-GB (EUCTR) | 16/11/2012 | 22/08/2012 | A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cellsfor the treatment of ... | A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. - EBSTEM A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cellsfor the treatment of ... | Recessive Dystrophic Epidermolysis Bullosa MedDRA version: 17.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive Dystrophic Epidermolysis Bullosa MedDRA version: 17.0;Level: SOC;Classification code 10010 ... | Product Name: Allogenic mesenchymal stromal cells Product Code: TC-MSC | King's College London | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 1;Phase 2 | United Kingdom | ||
| 7 | EUCTR2020-002936-55-CZ (EUCTR) | 03/08/2020 | Safety and Efficacy of Mesenchymal Stromal Cells Derived from Adipose Tissue of Non-related Donors in Patients with The Butterfly Disease: Clinical Trial Phase I/II Safety and Efficacy of Mesenchymal Stromal CellsDerived from Adipose Tissue of Non-related Donors in ... | Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II - MSC-EB Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cellsin Patients with Ep ... | Epidermolysis bullosa congenita;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Epidermolysis bullosa congenita;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonata ... | Product Name: allogeneic adipose tissue-derived MSC INN or Proposed INN: Human allogeneic adipose tissue-derived mesenchymal stem cells expanded Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED Product Name: allogeneic adipose tissue-derived MSC INN or Proposed INN: Human allogeneic adipose tis ... | Masarykova univerzita | NULL | NA | Female: yes Male: yes | 15 | Phase 1;Phase 2 | Czech Republic |